Fly News Breaks for November 6, 2019
Nov 6, 2019 | 08:42 EDT
SunTrust analyst David MacDonald raised his price target on DaVita to $72 after its "solid" Q3 results, with "decent" volumes, "strong" free cash flow, and "robust" share buybacks. The analyst also keeps his Hold rating on the stock, saying his optimism for the company's core dialysis business and its long-term integrated care opportunity is offset by the risks around labor costs, ballot initiatives, and slowing organic volume trends.
News For DVA From the Last 2 Days
There are no results for your query DVA